Furthermore, targeting AR with the antiandrogen enzalutamide (Enz) could restore sunitinib sensitivity in the sunitinib-resistant PDX mouse model, suggesting enhancing TKI efficacy through inhibition of AR to better suppress ccRCC progression [8]. This evidence concerns the gene AR and nonpapillary renal cell carcinoma.